The J&J Lung Cancer Innovation QuickFire Challenge will award up to $750,000 in non-dilutive grant funding and one year of optional residency at the new JLABS @ Shanghai for game-changing, outside-the-box solutions addressing the prevention, interception and cure for lung cancer.
Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths globally each year. Unlike other diseases, lung cancer is caused by prolonged environmental exposure to carcinogens that overwhelm a human’s natural defences and result in inflammation, genomic changes and ultimately tumour growth.
Although a global epidemic, it is unclear what makes one individual over another more susceptible to developing lung cancer.
Johnson & Johnson (China) Investment Ltd. and Johnson & Johnson Innovation LLC are committed to prioritising lung health.
Up to three innovators with the best ideas, technologies, or solutions that improves human healthcare related to preventing, intercepting or curing lung cancer will be awarded up to a total of $750,000 in grants, a voucher for one year of residency at JLABS @ Shanghai (optional), including a laboratory bench, workstation and access to the JLABS community, and mentorship from Johnson & Johnson Innovation and/or its affiliates.
The application deadline is 14 September 2018.
For more information, see here.